Addex Therapeutics vs Silo Pharma
ADXN and SILO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ADXN and SILO compare
Silo Pharma grew revenue faster over the last twelve months (−50.0% versus −92.6% for Addex Therapeutics).
Silo Pharma scores higher on the StockData Score (3 against 0 for Addex Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADXN | SILO |
|---|---|---|
| Size and price | ||
| Market cap | – | $2.9M |
| Share price | $4.06 | $1.84 |
| Change, 1 year | −53.9% | −72.8% |
| Change, 5 years | −97.1% | −98.7% |
| Beta (5Y) | 0.90 | 0.48 |
| Employees | 3 | 3 |
| StockData Score | ||
| Total score | 0 | 3 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 0 | 1 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 81.1× |
| P/B | – | 0.3× |
| Growth | ||
| Revenue growth (TTM) | −92.6% | −50.0% (better) |
| Revenue growth, 5Y average | −61.6% | 12.0% (better) |
| EPS growth (TTM) | −186% | – |
| Profitability | ||
| Operating margin | −9391% (better) | −12534% |
| Net margin | – | −10319% |
| FCF margin | −7244% | – |
| Return on equity | – | −55.3% |
| Financial health | ||
| Interest coverage | −181.0× | −112.8× (better) |
| Current ratio | 0.76 | 24.43 (better) |
| Altman Z-score | – | 0.87 |
| Piotroski F-score | – | 4 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 0.00% | 9.0% |
| Held by insiders | 15.5% | 13.8% |
| Insider net buying, 12 months | – | $2.1K |
| Short interest, % of float | – | 1.0% |
Go deeper
- ADXN stock overview
- ADXN income statement
- ADXN valuation and score
- SILO stock overview
- SILO income statement
- SILO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.